Application of lenvatinib/lenvatinib (Lenvima) in the treatment of lung cancer

Lenvatinib/Lenvatinib (Lenvatinib), as a multi-target tyrosine kinase inhibitor, mainly inhibits tumor angiogenesis and cell proliferation by blocking the VEGF, FGF and RET signaling pathways. Currently, it has been widely used in the treatment of various solid tumors such as renal cell carcinoma, hepatocellular carcinoma, thyroid cancer, and endometrial cancer. However, in the field of lung cancer, the application of lenvatinib is still in the exploratory stage and has not yet become a formally approved standard treatment regimen.

In some early studies, lenvatinib has shown certain anti-tumor activity, especially in patients with non-small cell lung cancer (NSCLC) with certain molecular characteristics. Due to its potent anti-angiogenic effects, researchers are trying to combine lenvatinib with immune checkpoint inhibitors (such as pembrolizumab or nivolumab) to enhance the immune response in the tumor microenvironment and thereby improve treatment efficacy. Early experimental results show that when combined with immune drugs, lenvatinib may improve the ability of immune drugs to enter tumor tissue by changing the tumor vascular structure and immune cell infiltration, which lays a theoretical foundation for its application in lung cancer.

Despite this, the official indications for lenvatinib in the treatment of lung cancer have not yet been announced, and more clinical trials are still needed to confirm its effectiveness and safety. Considering the complex pathological types and diverse molecular targets of lung cancer, current mainstream treatments are still dominated by targeted drugs based on driving genes such as EGFR, ALK, and ROS1. Lenvatinib, as an anti-angiogenic drug, is more likely to play an auxiliary role in combination therapy or post-drug resistance treatment.

In the future, with the in-depth research on the new generation of targeted lung cancer worldwide, lenvatinib is expected to become an important part of the combined strategy of multi-pathway targeting and immunotherapy, providing a new treatment direction for patients with advanced lung cancer.

Reference materials:https://www.lenvima.com/